. Author manuscript; available in PMC: 2015 Jun 18.

Published in final edited form as: Otolaryngol Head Neck Surg. 2014 Oct 30;152(1):23–41. doi: 10.1177/0194599814553930

Table 10.

Studies with Audiometric Data Showing ASA Confers Protection from Gentamicin-Associated Hearing Loss.

Author, Year	Study Design (sample size)	Patient Description	NSAID Evaluated	Hearing Evaluation	Follow-up Time	ASA Results	Placebo Results	Time from Exposure to Outcome	Additional Comments
Sha, 2006⁵⁹; Chen, 2007⁶⁰	Randomized double-blind placebo-controlled trial (n = 195)	ASA: 76 males and 13 females Placebo: 95 males and 11 females scheduled for gentamicin 80–160 mg intravenous twice per day	ASA 1 g Q8h ×14 d	Pure-tone audiograms; HL defined as 15 dB or more at 6 and 8k Hz	Day 1 of treatment, day of discharge, and 5–7 w after beginning treatment	3% (3/89) had HL ≥ 15 dB at 6000 Hz and at 8000 Hz P = .013	13% (14/106) had HL ≥ 15 dB at 6000 Hz and at 8000 Hz	Not further specified	Severity of illness requiring gentamicin may have been a theoretical confounder.
Behnoud, 2009⁵⁸	Randomized double-blind controlled trial (n = 60)	Age > 18 years, scheduled gentamicin 80 mg 3 times intravenous per day Exclusion criteria: preexisting HL, systemic disease, and pregnant	Experimental group: ASA 1.5 g/d × 7 d Control group: given placebo	PTA and SDS; HL defined as threshold shift of > 15 dB at 6 and 8 kHz	Baseline, 8, and 15 days after beginning treatment	3% (1/30) had HL ≥ 15 dB at 4000 Hz (P = .001) 3% (1/30) had HL ≥ 15 dB at 8000 Hz (P = .0014)	36% (11/30) had HL≥ 15 dB at 4000 Hz (P = .001) 20% (6/30) had HL ≥ 15 dB at 8000 Hz P=.0014)	8, 15 days	ASA was also associated with better PTAs in other frequencies. Patients had similar gender, age, weight, at baseline.

Abbreviations: ASA, aspirin (acetylsalicylic acid); HL, hearing loss; NSAID, nonsteroidal anti-inflammatory drugs; PTA, pure-tone average; SDS, speech discrimination scores.